New hope for Hard-to-Treat leukemia: triple drug combo shows promise
NCT ID NCT03862157
First seen Jan 12, 2026 · Last updated Apr 30, 2026 · Updated 15 times
Summary
This study is for adults newly diagnosed with a challenging form of acute myeloid leukemia (AML) that is either related to a prior blood disorder or caused by previous cancer treatment. The trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—to find the best dose and see how well it works. About 40 participants will receive this treatment to control the disease and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.